@yosimonwoodroffe: YO! Man – pre-order now! So... this is my new book, YO! Man - it's been a long time coming, and I'm happy to say it's out on June 4. YO! Man tells the story of how I went from being down on my luck and running out of money, to somehow turning it around: opening YO! Sushi, doing Dragons’ Den, hotels around the world… and everything that happened in between – with plenty of ups and downs along the way. I've always believed that the harder you work, the more you sweat, the luckier you get. And, if I can do it, anybody can! YO! Man – pre-order now! Links in bio...

Simon Woodroffe
Simon Woodroffe
Open In TikTok:
Region: GB
Monday 04 May 2026 18:00:00 GMT
1001
25
1
2

Music

Download

Comments

justcraiglife
JustCraig :
💪💪💪
2026-05-04 18:06:23
1
To see more videos from user @yosimonwoodroffe, please go to the Tikwm homepage.

Other Videos

SYMVESS: New Bioengineered Vein for Dialysis | A Future Alternative to Permcath? #SYMVESS #Dialysis #AVFistula #KidneyCare #MMDC Could a new bioengineered blood vessel help dialysis patients spend less time with a permanent catheter? SYMVESS, also known as an acellular tissue-engineered vessel (ATEV), is an emerging medical innovation being studied for hemodialysis access. It is designed to provide an alternative pathway for blood flow during dialysis and may offer new hope to patients who face delays or difficulties with traditional AV fistula access. In this video, discover how SYMVESS works, how it differs from a conventional AV fistula, and what recent Phase 3 research has revealed. In an interim analysis of 80 women receiving hemodialysis, the bioengineered vessel became usable in a median of 1.7 months, compared with 5.3 months for an AV fistula. Participants also averaged more catheter-free days during the first year. These early findings are promising, but further regulatory steps are needed before SYMVESS can be routinely used for dialysis access. Medical Disclaimer: This video is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. SYMVESS, Symvess dialysis, bioengineered blood vessel, bioengineered vein for dialysis, new dialysis technology, Permcath alternative, permanent dialysis catheter, AV fistula, AV graft for dialysis, hemodialysis access, dialysis access innovation, dialysis catheter infection, catheter free dialysis, ATEV medical technology, tissue engineered blood vessel, kidney failure treatment, dialysis patients, vascular access for dialysis, nephrology research, latest dialysis research 2026, MMDC Lahore.
SYMVESS: New Bioengineered Vein for Dialysis | A Future Alternative to Permcath? #SYMVESS #Dialysis #AVFistula #KidneyCare #MMDC Could a new bioengineered blood vessel help dialysis patients spend less time with a permanent catheter? SYMVESS, also known as an acellular tissue-engineered vessel (ATEV), is an emerging medical innovation being studied for hemodialysis access. It is designed to provide an alternative pathway for blood flow during dialysis and may offer new hope to patients who face delays or difficulties with traditional AV fistula access. In this video, discover how SYMVESS works, how it differs from a conventional AV fistula, and what recent Phase 3 research has revealed. In an interim analysis of 80 women receiving hemodialysis, the bioengineered vessel became usable in a median of 1.7 months, compared with 5.3 months for an AV fistula. Participants also averaged more catheter-free days during the first year. These early findings are promising, but further regulatory steps are needed before SYMVESS can be routinely used for dialysis access. Medical Disclaimer: This video is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. SYMVESS, Symvess dialysis, bioengineered blood vessel, bioengineered vein for dialysis, new dialysis technology, Permcath alternative, permanent dialysis catheter, AV fistula, AV graft for dialysis, hemodialysis access, dialysis access innovation, dialysis catheter infection, catheter free dialysis, ATEV medical technology, tissue engineered blood vessel, kidney failure treatment, dialysis patients, vascular access for dialysis, nephrology research, latest dialysis research 2026, MMDC Lahore.

About